Home Cart Sign in  
Chemical Structure| 555-66-8 Chemical Structure| 555-66-8

Structure of Shogaol
CAS No.: 555-66-8

Chemical Structure| 555-66-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Shogaol is a naturally occuring pungent component of ginger with anti-inflammatory and anticancer properties.

Synonyms: [6]-Shogaol; 6-Shogaol

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Shogaol

CAS No. :555-66-8
Formula : C17H24O3
M.W : 276.37
SMILES Code : CCCCC/C=C/C(CCC1=CC=C(O)C(OC)=C1)=O
Synonyms :
[6]-Shogaol; 6-Shogaol
MDL No. :MFCD01736094
InChI Key :OQWKEEOHDMUXEO-BQYQJAHWSA-N
Pubchem ID :5281794

Safety of Shogaol

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Caco-2 cells 5, 10, 20 μg/mL 24 hours To investigate the effects of 6-shogaol on glucose uptake and intestinal barrier integrity in Caco-2 cells. Results showed that 6-shogaol inhibited glucose uptake, down-regulated the expression of glucose transporters GLUT2 and SGLT1, and up-regulated the expression of tight junction proteins ZO-1, Occludin, and Claudin. Foods. 2023 Jan 21;12(3):503
R-CCRF-CEM (T-ALL) 10-200 µM 72 hours To evaluate the effect of 6-shogaol on the viability of R-CCRF-CEM cells, results showed that 6-shogaol inhibited cell viability at higher concentrations. J Cell Mol Med. 2021 May 3;25(13):6148–60
RN95 (B-ALL) 10-200 µM 72 hours To evaluate the effect of 6-shogaol on the viability of RN95 cells, results showed that 6-shogaol inhibited cell viability at higher concentrations. J Cell Mol Med. 2021 May 3;25(13):6148–60
CCRF-CEM (T-ALL) 10-200 µM 72 hours To evaluate the effect of 6-shogaol on the viability of CCRF-CEM cells, results showed that 6-shogaol inhibited cell viability at higher concentrations. J Cell Mol Med. 2021 May 3;25(13):6148–60
Nalm-6 (B-ALL) 10-200 µM 96 hours To evaluate the effect of 6-shogaol on the viability of Nalm-6 cells, results showed that 6-shogaol significantly inhibited cell viability at higher concentrations. J Cell Mol Med. 2021 May 3;25(13):6148–60

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 male mice Stress-induced IBS model Gavage 0.1 to 1 mg/kg Once daily for 2 weeks 6-Shogaol significantly increased the AWR score, number of defecation particles, and fecal water content of IBS mice in a dose-dependent manner, and increased inflammatory infiltration of the intestinal mucosa and inhibited the differentiation and regeneration of ICSCs Research (Wash D C). 2024 Nov 7;7:0524
C57BL/6j male mice Pressure-overload-induced heart failure model Oral 0.2 or 1 mg/kg Once daily for 8 weeks Prevented TAC-induced systolic dysfunction and cardiac hypertrophy, significantly inhibited TAC-induced increases in histone H3K9 acetylation Nutrients. 2023 May 8;15(9):2232
Wistar rats Rotenone-induced Parkinson's disease model Oral 10 and 20 mg/kg Daily administration for 28 days 6-Shogaol significantly improved rotenone-induced behavioral and biochemical abnormalities, including motor function, antioxidant status, inflammatory response, and neurotransmitter levels. Pharmaceuticals (Basel). 2024 Oct 9;17(10):1348
Mice Oxaliplatin-induced neuropathic pain model Intraperitoneal injection 10 mg/kg Single injection, lasting for 3 hours To evaluate the analgesic effect of [6]-Shogaol on oxaliplatin-induced cold and mechanical allodynia. Results showed that 10 mg/kg of [6]-Shogaol significantly alleviated oxaliplatin-induced cold and mechanical allodynia, lasting for 3 hours. Pharmaceuticals (Basel). 2022 Jun 8;15(6):726
Mice Oxaliplatin-induced neuropathic pain model Intraperitoneal injection 10 mg/kg Single administration, evaluated after 1 hour To evaluate the alleviating effect of [6]-Shogaol on oxaliplatin-induced cold and mechanical allodynia, results showed that [6]-Shogaol significantly alleviated pain. Pharmaceuticals (Basel). 2023 Oct 15;16(10):1465
C57BL/6 mice MPTP-induced Parkinson's disease model Oral 10 mg/kg/day Once daily for 3 days To investigate the protective effects of 6-shogaol against MPTP-induced movement impairment and dopaminergic neuronal damage. Results showed that 6-shogaol significantly improved motor coordination, increased the number of TH-positive cells in the substantia nigra pars compacta and TH-IR fiber intensity in the striatum, and inhibited microglial activation and increases in TNF-α, NO, iNOS, and COX-2 levels. Acta Pharmacol Sin. 2013 Sep;34(9):1131-9
Swiss albino mice Traumatic brain injury (TBI) model Intraperitoneal injection 10, 20 and 30 mg/kg/day Once daily for 14 days 6-Shogaol (higher dose) was able to attenuate anxiety/depression-like behaviors in mice with TBI. 6-Shogaol treatment also altered MDA formation and expressions of TNF-α and IL-1β that act as major inflammation-inducing cytokines in brain tissue. Additionally, brain BDNF levels were also affected by 6-Shogaol treatment. ACS Omega. 2021 Dec 28;7(1):140-148
Mice Pirt-GCaMP6s transgenic mice Ex vivo gastroesophageal-vagal preparation 100 μM Pretreatment for 30 min followed by vincristine application for 30 min in presence of 6-shogaol 6-shogaol attenuated vincristine-induced activation of vagal C-fibers via TRPA1 channel desensitization Molecules. 2022 Nov 2;27(21):7465
ICR mice LPS-induced sepsis-associated liver injury model Oral 20 mg/kg 7 consecutive days To investigate the protective effect of 6-Shogaol on LPS-induced liver injury. Results showed that 6-Shogaol significantly improved liver function markers (ALT and AST), enhanced antioxidant enzyme activities (SOD and CAT), reduced MDA levels, and alleviated inflammatory response by inhibiting the MAPK/NF-κB pathway. Nutrients. 2021 Sep 28;13(10):3427
C57BL/6J mice Methionine- and choline-deficient (MCD) dietary model of NASH Intraperitoneal injection 20 mg/kg Three times a week for four weeks 6-Shogaol effectively mitigated liver injury, inflammation, and fibrosis in MCD diet-fed mice by inhibiting oxidative stress, cell death, and endoplasmic reticulum stress. Molecules. 2024 Jan 15;29(2):419
Mice Cisplatin-induced acute kidney injury model Intraperitoneal injection 20 mg/kg Once daily for 3 consecutive days To evaluate the protective effect of 6-Shogaol on cisplatin-induced acute kidney injury. Results showed that 6-Shogaol ameliorated renal dysfunction and tubular injury, reduced oxidative stress, cell death, and inflammatory responses. Molecules. 2021 Sep 30;26(19):5931
BALB/c nude mice Ovarian cancer xenograft model Intraperitoneal injection 40 mg/kg and 60 mg/kg Once a day for two days 6-shogaol at 40 mg/kg and 60 mg/kg indicated lower tumor volumes compared with the control. The body weight of all groups was not significant. Int J Mol Sci. 2023 Jan 30;24(3):2639
NOD/SCID nude mice U937 xenograft model Intraperitoneal injection 50 mg/kg Once daily for 20 days Inhibited tumor growth of U937 xenograft and induced apoptosis in tumor cells Mol Cancer. 2013 Nov 12;12(1):135

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03698318 Healthy Subject Not Applicable Recruiting April 2019 France ... More >> Biofortis Mérieux Nutrisciences Recruiting Saint-Herblain, France, 44800 Contact: Sophie Schmid    +33(0)240205799    sophie.schmid@mxns.com Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.62mL

0.72mL

0.36mL

18.09mL

3.62mL

1.81mL

36.18mL

7.24mL

3.62mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories